BPMC Logo

Blueprint Medicines Corp (BPMC) Stock Forecast & Price Prediction

Live BPMC Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$93.94

-1.25 (-1.31%)

12 Month Price Forecast For BPMC

$93.94
Current Price
$6.05B
Market Cap
20 Ratings
Buy 14
Hold 5
Sell 1
Wall St Analyst Ratings

Distance to BPMC Price Forecasts

+79.9%
To High Target of $169.00
+38.4%
To Median Target of $130.00
-11.6%
To Low Target of $83.00

BPMC Price Momentum

-10.5%
1 Week Change
-10.4%
1 Month Change
+7.3%
1 Year Change
+7.7%
Year-to-Date Change
-22.9%
From 52W High of $121.90
+30.0%
From 52W Low of $72.24

๐Ÿค” Considering Blueprint Medicines (BPMC)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 11:40 AM UTC

BPMC Analyst Ratings & Price Targets

Based on our analysis of 29 Wall Street analysts, BPMC has a bullish consensus with a median price target of $130.00 (ranging from $83.00 to $169.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $93.94, the median forecast implies a 38.4% upside. This outlook is supported by 14 Buy, 5 Hold, and 1 Sell ratings.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

BPMC Analyst Consensus

14
Buy
5
Hold
1
Sell

BPMC Price Target Range

Low
$83.00
Average
$130.00
High
$169.00
Current: $93.94

Latest BPMC Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for BPMC.

Date Firm Analyst Rating Change Price Target
Feb 14, 2025 Needham Ami Fadia Buy Reiterates $133.00
Feb 14, 2025 HC Wainwright & Co. Andrew Fein Buy Reiterates $135.00
Feb 14, 2025 JMP Securities Reni Benjamin Market Outperform Reiterates $125.00
Feb 13, 2025 Needham Ami Fadia Buy Reiterates $133.00
Feb 4, 2025 JP Morgan Brian Cheng Overweight Maintains $129.00
Jan 27, 2025 Piper Sandler Christopher Raymond Neutral Maintains $119.00
Jan 15, 2025 JMP Securities Reni Benjamin Market Outperform Reiterates $125.00
Jan 13, 2025 Needham Ami Fadia Buy Reiterates $135.00
Jan 13, 2025 Wedbush David Nierengarten Outperform Reiterates $124.00
Jan 2, 2025 Stephens & Co. Overweight Reiterates $0.00
Dec 17, 2024 Needham Buy Reiterates $0.00
Dec 11, 2024 Guggenheim Michael Schmidt Buy Reiterates $0.00
Dec 9, 2024 JMP Securities Reni Benjamin Market Outperform Reiterates $125.00
Nov 18, 2024 JMP Securities Reni Benjamin Market Outperform Reiterates $125.00
Nov 15, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $135.00
Nov 15, 2024 Needham Ami Fadia Buy Reiterates $135.00
Nov 14, 2024 JP Morgan Brian Cheng Overweight Initiates $126.00
Oct 31, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $135.00
Oct 31, 2024 Needham Ami Fadia Buy Maintains $135.00
Oct 31, 2024 Wells Fargo Derek Archila Overweight Maintains $151.00

Stocks Similar to Blueprint Medicines Corp

The following stocks are similar to Blueprint Medicines based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Blueprint Medicines Corp (BPMC) Financial Data

Blueprint Medicines Corp has a market capitalization of $6.05B with a P/E ratio of -87.8x. The company generates $508.82M in trailing twelve-month revenue with a -13.2% profit margin.

Revenue growth is +103.4% quarter-over-quarter, while maintaining an operating margin of -28.2% and return on equity of -31.3%.

Valuation Metrics

Market Cap $6.05B
Enterprise Value $6.11B
P/E Ratio -87.8x
PEG Ratio -99.9x
Price/Sales 11.9x

Growth & Margins

Revenue Growth (YoY) +103.4%
Gross Margin +94.9%
Operating Margin -28.2%
Net Margin -13.2%
EPS Growth +103.4%

Financial Health

Cash/Price Ratio +10.3%
Current Ratio 2.8x
Debt/Equity 242.5x
ROE -31.3%
ROA -11.9%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Blueprint Medicines Corp logo

Blueprint Medicines Corp (BPMC) Company Overview

About Blueprint Medicines Corp

What They Do

Develops precision therapies for cancer and blood disorders.

Business Model

The company focuses on creating targeted medicines for specific genomic alterations in cancers and blood disorders, generating revenue through the sale of these therapies post-approval. It also engages in collaboration and licensing agreements with other pharmaceutical companies to expand its reach and pipeline.

Additional Information

Blueprint Medicines is headquartered in Cambridge, Massachusetts, and has a diverse pipeline that includes treatments for various forms of cancer and blood disorders. The company was previously known as Hoyle Pharmaceuticals, Inc. and has established partnerships with several notable firms in the pharmaceutical industry.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

638

CEO

Ms. Kathryn Haviland M.B.A.

Country

United States

IPO Year

2015

Blueprint Medicines Corp (BPMC) Latest News & Analysis

BPMC stock latest news image
Quick Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) will hold a live conference call and webcast on February 5, 2025, at 8:00 a.m. for investors and stakeholders.

Why It Matters

Blueprint Medicines' upcoming conference call may reveal key updates on financial performance, drug development, or strategic plans, influencing stock price and investment decisions.

Source: PRNewsWire
Market Sentiment: Neutral
BPMC stock latest news image
Quick Summary

Blueprint Medicines (BPMC) is not expected to achieve an earnings beat in its upcoming report due to lacking the necessary key ingredients. Investors should prepare for this outcome.

Why It Matters

Blueprint Medicines may report disappointing earnings, potentially leading to a decline in share price and affecting investor confidence. Key expectations could influence trading strategies.

Source: Zacks Investment Research
Market Sentiment: Negative
BPMC stock latest news image
Quick Summary

Blueprint Medicines Corporation (BPMC) has reached a key support level and experienced a "golden cross," indicating potential upward momentum in its stock.

Why It Matters

The "golden cross" suggests bullish momentum for BPMC, indicating potential price increases, making it an appealing option for traders seeking upward trends.

Source: Zacks Investment Research
Market Sentiment: Positive
BPMC stock latest news image
Quick Summary

Peak revenue opportunity for systemic mastocytosis is updated to $4 billion, with AYVAKIT expected to reach $2 billion by 2030. BLU-808 shows promising results in Phase 1 study. CEO to present at J.P. Morgan conference.

Why It Matters

Peak revenue potential for systemic mastocytosis is now estimated at $4 billion, driven by strong AYVAKIT sales and new data on BLU-808, signaling growth opportunities for investors.

Source: PRNewsWire
Market Sentiment: Neutral
BPMC stock latest news image
Quick Summary

Blueprint Medicines (BPMC) shares rose significantly with above-average trading volume, though recent earnings estimate revisions may not lead to further price increases soon.

Why It Matters

Surging shares and higher trading volume suggest increased investor interest in Blueprint Medicines, but mixed earnings revisions indicate potential volatility ahead.

Source: Zacks Investment Research
Market Sentiment: Positive
BPMC stock latest news image
Quick Summary

BPMC stock surged 18% following the company's positive 2025 outlook, highlighting expected growth in Ayvakit sales and advancements in its pipeline.

Why It Matters

BPMC's 18% stock rally signals strong market confidence in its growth potential, driven by positive sales forecasts for Ayvakit and advancements in its drug pipeline.

Source: Zacks Investment Research
Market Sentiment: Positive

Frequently Asked Questions About BPMC Stock

What is Blueprint Medicines Corp's (BPMC) stock forecast for 2025?

Based on our analysis of 29 Wall Street analysts, Blueprint Medicines Corp (BPMC) has a median price target of $130.00. The highest price target is $169.00 and the lowest is $83.00.

Is BPMC stock a good investment in 2025?

According to current analyst ratings, BPMC has 14 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $93.94. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for BPMC stock?

Wall Street analysts predict BPMC stock could reach $130.00 in the next 12 months. This represents a 38.4% increase from the current price of $93.94. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Blueprint Medicines Corp's business model?

The company focuses on creating targeted medicines for specific genomic alterations in cancers and blood disorders, generating revenue through the sale of these therapies post-approval. It also engages in collaboration and licensing agreements with other pharmaceutical companies to expand its reach and pipeline.

What is the highest forecasted price for BPMC Blueprint Medicines Corp?

The highest price target for BPMC is $169.00 from at , which represents a 79.9% increase from the current price of $93.94.

What is the lowest forecasted price for BPMC Blueprint Medicines Corp?

The lowest price target for BPMC is $83.00 from at , which represents a -11.6% decrease from the current price of $93.94.

What is the overall BPMC consensus from analysts for Blueprint Medicines Corp?

The overall analyst consensus for BPMC is bullish. Out of 29 Wall Street analysts, 14 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $130.00.

How accurate are BPMC stock price projections?

Stock price projections, including those for Blueprint Medicines Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.